Gas exchange and pulmonary hypertension following acute pulmonary thromboembolism: has the emperor got some new clothes yet?

John Y. C. Tsang,¹ James C. Hogg²

¹Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; ²Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada

Abstract: Patients present with a wide range of hypoxemia after acute pulmonary thromboembolism (APTE). Recent studies using fluorescent microspheres demonstrated that the scattering of regional blood flows after APTE, created by the embolic obstruction unique in each patient, significantly worsened regional ventilation/perfusion (V/Q) heterogeneity and explained the variability in gas exchange. Furthermore, earlier investigators suggested the roles of released vasoactive mediators in affecting pulmonary hypertension after APTE, but their quantification remained challenging. The latest study reported that mechanical obstruction by clots accounted for most of the increase in pulmonary vascular resistance, but that endothelin-mediated vasoconstriction also persisted at significant level during the early phase.

Keywords: fluorescent microspheres, pulmonary vasoconstriction, regional blood flow, ventilation-perfusion mismatch.

Pulm Circ 2014;4(2):220-236. DOI: 10.1086/675985.

More than 30 years ago, Eugene Robin commented on the problems of diagnosing acute pulmonary thromboembolism (APTE) by referring the physicians' attitudes to the emperor's vanity in Hans Christian Andersen's fable.^{1,2} Although significant advances have occurred over the years,³⁻⁵ some aspects of its pathophysiology remain puzzling.⁶

This report provides an updated review of the literature, published mostly from 1980 onward, specifically addressing the mechanisms of hypoxemia and pulmonary hypertension (PH) after APTE. The emphasis is on the elucidation of the underlying pathophysiological principles and bringing them to the bedside, rather than on presenting meta-analysis or clinical trials. It also allows for occasional personal perspectives but has excluded recent works at the molecular level.

GAS EXCHANGE IN APTE

Hypoxemia is a common and nonspecific feature of APTE.^{7,8} It remains mysterious because the patient's arterial oxygen tension (PaO₂) is often unpredictable and correlates poorly with embolic load.⁹⁻¹¹ It is also associated with very different V/Q (ventilation/perfusion ratio) pat-

terns measured by the multiple inert gas elimination technique (MIGET) among similar subjects¹² or in the same subject over time.^{12,13} The roles of anatomical shunts may be important among a minority of patients but are questionable in the rest. These variations in gas exchange are clinically relevant in a negative way, because blood gas results do not contribute to defining pretest probabilities in the interpretation of nuclear scans.^{1,14,15}

The major purpose of this communication is to discuss the key factors that determine the degree of hypoxemia after APTE and their relevance to 5 commonly asked questions:

1. Why do patients with APTE present with such a wide range of hypoxemia?
2. Why do many patients with APTE have relatively clear chest X-rays while severely hypoxic?
3. Can patients with significant APTE present with relatively normal PaO₂?
4. Why does hypoxemia worsen when cardiac output is increased?
5. Why do some patients with APTE have pulmonary infarcts and the others do not?

Address correspondence to Dr. John Tsang, iCAPTURE Research Lab, 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada. E-mail: jtsang@mail.ubc.ca.

Submitted October 25, 2013; Accepted February 17, 2014; Electronically published April 28, 2014.

© 2014 by the Pulmonary Vascular Research Institute. All rights reserved. 2045-8932/2014/0402-0010. \$15.00.

MECHANISMS OF HYPOXEMIA FOLLOWING APTE

Ventilation-perfusion mismatch as a key factor

Previous investigators have attempted to map V/Q abnormalities in the embolized lung. Burton et al.¹⁶ showed the redistribution of regional blood flow (Q) versus regional ventilation (V), using nuclear scans, but their data lacked the required resolution. Others used radioactive macroaggregates to confirm that regional blood flow was significantly diverted from the embolized area but reported no data on ventilation.^{17,18} Results obtained from MIGET studies on APTE showed only abstract V/Q distributions based on a mathematical model.¹² In recent years, the fine images from computed tomography angiograms (CTAs) provided excellent information on the pulmonary vasculature but none on ventilation, even though there are now encouraging developments in single-photon-emission computed tomography (SPECT V/Q) that can facilitate more research in this field.¹⁹

The simultaneous measurement of regional V and Q in small regions of the embolized lung was first accomplished more than a decade ago, by investigators who used a technique based on aerosolized and injected fluorescent microspheres (FMSs).²⁰⁻²² Their data made it possible to reconstruct all regions of the embolized lung post mortem, with each region designated for its own V/Q ratio²³ and mapped in three-dimensional (3D) coordinates. All emboli locations were also marked.²⁴ Using appropriate computer software, their reports provided more reliable and comprehensive results than previous publications^{25,26} because of the direct measurements of V and Q in situ and the additional information that could be visualized on an anatomical model, e.g., dorsal versus ventral and hilar versus subpleural areas.

In an established porcine model of APTE and at different time points during the experiment, regional V and Q of the lungs were marked before and after APTE by FMSs of various colors and sizes, i.e., using 1- μ m FMSs for aerosolization into the airway for labeling V and 15- μ m FMSs for injection into the femoral vein for labeling Q.²⁴ Pigs were chosen for these experiments because of their strong pulmonary vasoconstrictive response to various physiological stimuli, such as hypoxemia.²⁷ They were studied in the prone position because it is their normal physiological posture.²⁴

At the end of the experiment, the lungs were removed from the thorax, the pulmonary vasculature was flushed with normal saline, and the inflated lungs were air-dried at room temperature for 3 days. The lungs were then sliced into about 1,000 pieces, with each sample (2 cm³) recorded for its weight, 3D location, presence of emboli, large air-

way, etc. (Fig. 1). The fluorescent intensities of all FMSs embedded in each sample provided the simultaneous V and Q data at the time of marking (Fig. 2). After the regional V/Q and measured gas tensions in the venous blood were obtained, the estimated pulmonary capillary O₂ and CO₂ tension in each sample could be calculated (see below),^{23,24} along with the information on its anatomical location in relation to the clots. Furthermore, the absolute amount of V and Q in each sample, in milliliters per minute, could be calculated when the cardiac output, minute ventilation, and dead space were known.

Because of the high affinity of oxygen to hemoglobin and the complete diffusion of oxygen across the alveolar membrane, the oxygen tension at the alveolar (P_AO₂), pulmonary capillary (P_cO₂), and arterial (P_aO₂) levels were considered equivalent for practical purposes, i.e., P_AO₂ = P_cO₂ = P_aO₂. Similarly, for CO₂, because of its high diffusibility and solubility, P_ACO₂ = P_cCO₂ = P_aCO₂, using the same notation.

The data showed that a considerable amount of the regional blood flow in the embolized lung was mechanically diverted to the less embolized regions, resulting in many low-V/Q units there. This was mainly due to the increased denominator (Q) in the V/Q of these regions, where V generally remained stable.²⁴ Small decreases in V/Q between good matching, or V/Q = 0.86, and V/Q = 0 could dramatically reduce P_cO₂, as the curvilinear line

Figure 1. Cross section of the embolized lung embedded in a foam case. Each lung was then sliced vertically and horizontally into approximately 1,000 pieces of 2 cm³ each. The arrows point to the locations of clots.

Figure 2. Red dots represent regions where the blood flow was reduced after acute pulmonary thromboembolism, blue dots represent regions where blood flow was maintained, and green dots represent regions where blood flow was increased. Yellow dots mark the locations of major emboli.

moved leftward along the flat portion of the O_2 - CO_2 diagram (Fig. 3).²⁸⁻³⁰ (For more details, see the appendix.)

Thus, the most important mechanism of hypoxemia following APTE is the creation of these low- V/Q units

as a result of the mechanical obstruction by the clots *in situ*.^{24,31} Simultaneously, high- V/Q units and physiological dead space are also created in areas where the denominator Q is much reduced, usually in regions distal to the emboli, i.e., the peripheral subpleural regions. These high- V/Q units, created in the way opposite that for the low- V/Q units, are described in the bent portion on the right side of the curve (Fig. 3) and have a greater effect on P_ACO_2 than on P_AO_2 . In short, there is a remarkable V/Q heterogeneity due to the scattering of Q in the presence of obstructing clots within the pulmonary vasculature. Even though V changes modestly in the same direction as Q , it does so to a much lesser extent.²⁴ APTE is a vascular disease and not so much a ventilation problem.³² The observation that V remains comparatively stable compared to Q following APTE probably explains why many MIGET studies showed increases in low- V/Q units but little true shunt ($V/Q = 0$), because V is rarely 0 even at higher Q .^{33,34}

Cardiac output as a confounding factor

Previous studies have shown that gas exchange often worsened with increasing cardiac output (Q_t) after APTE.³⁴ However, this is opposite to what one may expect from Fick's equation, in that higher Q_t in a steady state leads to improvement in venous oxygen tension (PvO_2) and subsequently better PaO_2 at a given venous admixture.

On the other hand, this contradiction is explained by an important and opposite mechanism, in which any in-

Figure 3. O_2 - CO_2 diagram after acute pulmonary thromboembolism in room air. Normal arterial PO_2 and PCO_2 are marked at 100 and 40 Torr, respectively, with good ventilation-perfusion (V - Q) matching, representing V/Q at about 0.86. For practical purposes, $P_AO_2 = P_cO_2 = PaO_2$, and $P_ACO_2 = P_cCO_2 = PaCO_2$ (i.e., alveolar, capillary, and arterial values are the same; see text). I: inspired gas point.

crease in total pulmonary blood flow (or Q_t) after APTE also results in a greater diversion of flow to the less embolized regions (with an already low V/Q), since the extra flow cannot go beyond the obstructing clots. Consequently, the even lower- V/Q units in these open regions worsen the hypoxemia.

Manier and Castaing³⁵ reported that oxygen transport in patients with APTE was improved by dobutamine, mostly because of improved Q_t , even though their concomitant PaO_2 fell because of worsening $V-Q$ mismatch shown in the simultaneous MIGET data. Others showed similar results using fluid and other vasopressors.¹⁸ A recent study also confirmed that when Q_t was increased intermittently by dobutamine after APTE, PaO_2 did not improve and sometimes worsened.³⁶ Upon further analysis, this variation of hypoxemia at higher Q_t was mostly accounted for by the interplay between the beneficial effect of higher PvO_2 on PaO_2 and the deleterious effect of worsening $V-Q$ mismatch, caused by the maldistribution of regional Q , as demonstrated by the FMS data.³⁶

Earlier reports have shown that during severe shock following acute pulmonary embolism, the degree of hypoxemia did not reflect the severity of embolic obstruction.³⁷ To interpret these data in another way, when pulmonary blood flow becomes dangerously low, there is simply insufficient Q to create more low- V/Q units, and patient's blood gases may look less life-threatening than expected.

Thus, if a patient is being resuscitated during severe shock when PvO_2 is extremely low, significant increases in Q_t may result in dramatic improvement in PvO_2 and subsequently PaO_2 . On the other hand, if the patient is hemodynamically more stable, higher Q_t will result in even more Q to the less embolized regions, resulting in worsening hypoxemia by outweighing the positive effect of a slightly higher PvO_2 ; i.e., the improvement in PvO_2 in a stable patient is less useful, as it sits on the flatter portion of the hemoglobin-oxygen dissociation curve. Thus, Q_t serves as a confounding variable on hypoxemia because it can affect PaO_2 in either direction after APTE, depending on PvO_2 , which reflects on the adequacy of the systemic circulation.

Preexisting cardiopulmonary status as a contributing factor

Patients with preexisting cardiopulmonary diseases and disabilities are susceptible to APTE^{38,39} and readily suffer more hypoxemia beyond their compromised baseline conditions. Given their already lower PaO_2 or PvO_2 prior to this aggravation, any increase in $V-Q$ mismatch or compromise in hemodynamics will result in a sharper decrease in PaO_2 ,⁴⁰ as the oxygen saturation drops quickly

along the steep slope of the hemoglobin-oxygen dissociation curve.⁴¹

Because of its stealthy nature, APTE sometimes coexists with and is masked by the underlying conditions, such as exacerbation of chronic obstructive pulmonary disease (COPD),⁴²⁻⁴⁴ idiopathic pulmonary fibrosis,⁴⁵ congestive heart failure,⁴⁶ adult respiratory distress syndrome,^{47,48} and sepsis,⁴⁹ to name just a few.

Time as a forgotten factor

APTE is a dynamic disease. Hypoxemia occurs acutely at the onset but generally resolves toward the preembolized level over time, with or without treatment with heparin.^{12,24,50} This is partly due to the movement or breakdown of some nonfibrinized clots and partly due to the accommodation of the more recruited pulmonary vasculature, as regional blood flow becomes more evenly distributed.²⁴

Previous data obtained from MIGET were reported as histograms, showing V/Q distribution from 0 to infinity. They consistently showed that under normal conditions, the vast majority of V and Q occurred when V/Q was about 1, depicted as a narrow central peak on the graph. However, after APTE, the V/Q pattern changed immediately, with many V/Q units in the low ($V/Q < 0.5$) and high ($V/Q > 10$) ranges created where there were none before. However, over time these remarkable changes gradually became more homogeneous, with ratios in the extreme ranges disappearing and merging toward the middle, where a much broadened central peak now appeared, at $V/Q \geq 1$.⁵⁰

Pulmonary edema, anatomical shunts, and atelectasis as minor factors

Data obtained from animal studies have shown only mild pulmonary edema following embolic injury.^{51,52} The extravascular lung water was 4.8 ± 0.84 g/g of dry lung, which was higher than the control value of 4.1 ± 0.5 ⁵³ but not in the range in which alveolar flooding resulted in significant hypoxemia.

Except in patients with significant heart failure, pulmonary edema after APTE is generally not a primary determinant of hypoxemia. Indeed, chest X-ray and CTA studies often fail to demonstrate pulmonary vascular congestion in most cases of APTE^{5,54} and sometimes show oligemia instead.⁵⁵ In fact, when clinicians encounter patients with severe hypoxemia and their unremarkable chest X-rays, they should suspect APTE as the cause of the hypoxemia.

Patent foramen ovale has been observed as an occasional cause of hypoxemia after APTE, and it has inde-

pendent prognostic implications.⁵⁶ However, it is not common in the general population, and its relevance depends on the size of the foramen and concomitant right atrial pressure. Recent advances in ultrasound imaging have also revealed previously less well-known intrapulmonary shunts,⁵⁷⁻⁵⁹ but their roles in APTE specifically remain to be ascertained.

Atelectasis and pleural effusion are seen on chest X-ray in patients with isolated APTE, even without other comorbidities,^{54,60} such as trauma or malignancies. In many cases, the involved areas are too small to account for life-threatening hypoxemia. They generally play a minor role in the overall venous admixture and are unlikely to be physiologically significant. In fact, most of these patients hyperventilate with high minute ventilation. On presentation they have low P_aCO_2 ,⁶¹ except in massive cases,⁶² where the dead space is huge.

Baroreceptors, surfactant, and red blood cell transit time as speculative factors

Several ideas have been propagated through the years but not backed up by more thorough research. These speculations include changes in baroreceptor control,^{63,64} loss of surfactant,^{65,66} reduction in carbon monoxide transfer,^{67,68} and shortened red blood cell transit time (T_{RBC}).⁶⁹ While the latter may be shortened because of high flow in some regions, it is always sufficient for diffusion of oxygen to hemoglobin across the alveolar epithelium.^{70,71} The calculation of this transit time, T_{RBC} (s) = regional blood volume (mL)/regional blood flow (mL/s), is to be differentiated from the V/Q with no unit, which describes the relative intake of oxygen from V in relation to the removal of oxygen by red blood cells delivered by Q.

ALVEOLAR CO_2 TENSION (P_ACO_2) AND REGIONAL VENTILATION SHIFTS FOLLOWING APTE

Because of the increased V/Q heterogeneity after APTE, P_ACO_2 also varies significantly. The arterial to end-expiratory CO_2 gradient is often seen clinically.⁷² Some investigators even suggested using this CO_2 gradient to confirm the diagnosis.⁷³ At any rate, the alterations of P_ACO_2 have their own pathophysiological effects in the embolized lung.

Previous studies reported that temporary unilateral pulmonary artery occlusion by inflation of a balloon-tipped catheter resulted in shifts of ventilation away from the obstructed side, where the overall V/Q was high.^{74,75} Furthermore, such changes could be mitigated by inhalation of CO_2 .⁷⁶ The proposed mechanism was presumably one

of hypocapnic bronchoconstriction and reduction in parenchymal compliance (pneumoconstriction) in the affected lung (high V/Q), where local airway narrowing and increased tissue resistance were mediated by lowered P_ACO_2 .^{77,78} On the other hand, the contralateral lung, which received more diverted flow (Q), now had a lower overall V/Q and thus higher P_ACO_2 . This resulted in more bronchodilation and increased parenchymal compliance (pneumodilation), rendering this lung able to receive more ventilation. Thus, V/Q or P_ACO_2 affected bronchial tone in a homeostatic way.

In the hypocapnic regions, the rise in tissue pH was mainly due to the decrease in blood flow and CO_2 delivery. When acetazolamide, a carbonic anhydrase inhibitor, was given to slow the change in tissue alkalosis during vascular occlusion, it reduced the rate of ventilation shift. This observation further supported the concept of local regulation of ventilation by regional CO_2 .⁷⁹

These experimental findings were later extended to studies of APTE. Nadel et al.⁸⁰ reported that after barium sulfate microembolism, there was a shift in ventilation to the unaffected areas, resulting in more atelectasis of the embolized regions due to alveolar duct constriction. Levy and Simmons⁸¹ also showed that there were again shifts in ventilation between different regions of the embolized lung, where blood clots created hypoperfused areas beyond the vascular obstruction, not unlike those created by the balloon-tipped catheters. They reported that regions of higher V/Q, and thus lower P_ACO_2 , redistributed ventilation away to the lower-V/Q regions and that these changes were again attenuated by inhalation of CO_2 . Using FMSs, Tsang et al.⁸² showed that the magnitude of these ventilation shifts was related to the changes in P_ACO_2 , particularly when it went below 20 Torr. Note that these changes in regional ventilation were not caused by any mechanical factors, such as airway edema or secretions, as seen in other forms of acute lung injury.

Hypoxic pulmonary vasoconstriction and hypocapnic bronchoconstriction are both homeostatic mechanisms to improve V-Q matching in a diseased lung, with the former occurring in the vasculature, responding to regional O_2 tension,^{83,84} and the latter occurring in the airway, responding to regional CO_2 tension. The roles of collateral ventilation and bronchial circulation in the regulation of regional ventilation in APTE are not well studied but are arguably mitigated by their random distribution between the embolized and nonembolized regions.

Clinically, patients often hyperventilate, and yet regional atelectasis is still seen.⁶⁰ One may postulate whether these reductions in regional ventilation are caused by ventilation shifts near the embolized regions, rather than from loss of

surfactant^{65,66} or splinting due to pleuritic pain. Whether these changes are potential sources of error in the interpretation of nuclear scan should be debated, as finding low V and Q at the same embolized area diminishes the diagnostic certainty reported by the radiologists.^{85,86}

ANSWERING THE 5 COMMONLY ASKED QUESTIONS

Why do patients with APTE present with such a wide range of hypoxemia?

Clinically, blood gas results are nondiagnostic.^{87,88} Earlier studies reported that patients with APTE present with a wide range of PaO₂ and very different V/Q patterns.⁸⁹ Some authors have proposed odd mechanisms, such as partial inhibition of hypoxic pulmonary vasoconstriction.⁹⁰ The actual reasons, with better hindsight, include (1) the unpredictable 3D locations of the clots, leading to infinite possibilities of regional blood flow diversion, thus creating a very different V/Q pattern each time;^{91,92} (2) the concomitant Qt acting as a confounding factor, which can range from hyperdynamic state to profound shock; (3) the time delay from the onset of disease; and (4) the simultaneous minute ventilation in compensation, which can also be highly variable. Furthermore, the preexisting conditions of the patients, such as cardiopulmonary diseases, obesity, postoperative pain, neuromuscular disorders, and presence of patent foramen ovale, introduce even more complexities.

Can patients with significant APTE present with relatively normal PaO₂?

It is rare. Table 1 shows the favorable and unfavorable factors that can determine PaO₂ after APTE. Unless all the favorable factors are lined up simultaneously, increases in the alveolar arterial oxygen gradient can be expected. Note that both saddle and subsegmental emboli can result in less mechanical scattering of pulmonary blood flow, even though their hemodynamic impacts are very different. To the extent that PvO₂ becomes very low in central emboli, causing obstructive shock, PaO₂ will still be depressed despite reduced diversion of blood flow. The explanation of normal PaO₂ in massive APTE based on blockade of the prostaglandin pathway is unfounded.¹⁰

Why do many patients with APTE have clear chest X-rays while severely hypoxic?

Mathematically, V/Q is determined by both the numerator and the denominator. Lowering of V/Q can be achieved by reducing V, increasing Q, or both. Severity of hypoxemia is often intuitively interpreted with the amount of

chest X-ray infiltrates, because the extent of pus, fluid, blood, or proteinaceous materials in the airspace correlates roughly to the reduction in alveolar ventilation by these materials (Fig. 4).⁹³ However, in the case of APTE, the opposite is true. The low V/Q is due to high Q rather than low V (Fig. 5). Thus, when V is maintained, the chest X-ray will be surprisingly unremarkable,^{54,55} despite significant hypoxemia. A V/Q scan¹⁵ or CTA⁹⁴ will further confirm the diagnosis.

Why does hypoxemia worsen when Qt is increased?

Previous investigators reported that PaO₂ correlated inversely with Qt in many different settings, i.e., under normal conditions⁹⁵ and in pulmonary edema,⁹⁶ COPD,⁹⁷ and APTE.^{25,35,98} Some suggested that this inverse correlation was due to the abolition of hypoxic pulmonary vasoconstriction due to the concomitant higher PvO₂.⁹⁹ As it turns out, the answer lies mostly in the heterogeneity of regional blood flow.^{17,18}

Despite the neat depiction of regional blood flow into different zones, as defined by pulmonary arteriolar pressure (Pa), alveolar pressure (P_A), and pulmonary venous pressure (Pv),¹⁰⁰⁻¹⁰² there is inherently a good deal of heterogeneity of Q even within the same zone, as defined by the Starling forces. Besides gravity, other determinants include radial gradient from the hilum,¹⁰³ metabolic factors such as PaO₂ and PaCO₂,¹⁰⁴ posture,^{105,106} temporal heterogeneity,¹⁰⁷ and uneven distribution of vascular resistance in arterial and venous beds.¹⁰⁸⁻¹¹⁰

Given any preexisting perfusion heterogeneity, even in normal condition, it worsens with increased total flow. In other words, when Qt increases, the mean of all Qs within the lung increases. So does the standard deviation of Q;⁶⁹ i.e., some regions receive disproportionately higher flow at the expense of others. Thus, unless V can very precisely match Q in the millions of alveoli, an unlikely scenario, V/Q heterogeneity will increase at higher Qt. The culminating result is a higher alveolar arterial oxygen gradient.

Specifically in APTE, when total pulmonary blood flow or Qt increases, it will cause even more exacerbation of V/Q heterogeneity by diverting more Q to the already lower-V/Q units, because the remaining pulmonary vasculature is mechanically obstructed by the clots.^{17,18,24} Thus, PaO₂ sometimes drops when Qt increases in APTE.

Why do some patients with APTE have pulmonary infarcts and others do not?

Pulmonary infarcts¹¹¹ after APTE are usually found in the subpleural regions because they are located beyond the embolic obstruction, where the regional blood flow is low.²⁴ They predispose to tissue ischemia, leading to ne-

Table 1. Favorable and unfavorable conditions that determine the degree of hypoxemia after acute pulmonary thromboembolism

Factor	Most favorable	Intermediate	Least favorable
Clot size and number	Small	Medium	Large
Clot location	Saddle or subsegmental	Segmental	Proximal within 2 generations
Time of measurement	Late, treated	Within 24 hours	Within a few hours
Qt, PvO ₂	Normal to high	Low	Obstructive shock
Preexisting diseases or PaO ₂	Normal	Mild	Severe
Preexisting risks or disability	Unremarkable	Moderate	Advanced
Minute ventilation	High and compensated	Early fatigue	Low
CO ₂ -induced ventilation shifts	Substantial	Moderate	Minimal
Shunts, PFO	Absent	Small	Large

Note: Unless all favorable conditions occurred at the same time, some increase in the alveolar arterial oxygen gradient could be expected. Qt: cardiac output; PvO₂: venous oxygen tension; PaO₂: arterial oxygen tension; PFO: patent foramen ovale.

crosis. In addition, the increased inflow of blood from the bronchial circulation under systemic pressure to these underperfused locations does not always allow good drainage into the pulmonary veins, especially when left atrial pressure is concomitantly high. Consequently, there is also venous infarct of congestion, stasis, and hemorrhage.¹¹²

Reported risk factors for this complication include (1) lung cancer, in which Virchow's triad operates in situ, (2) left heart failure, in which the pulmonary venous congestion occurs, and (3) shock, in which the pulmonary and collateral flows are poor.^{113,114} Patients who have normal heart function are less likely to progress into the final stage of venous infarction.¹¹² The healthier patients

with APTE who developed only pulmonary hemorrhage but stopped short of infarction, according to symptoms and follow-up chest X-rays, also recovered more quickly, usually within 7 days.

Interestingly, the use of vasodilators, such as nitroglycerin, hydralazine, nitroprusside, and prazosin, increased the risk of pulmonary infarct after APTE.¹¹⁵ Some attribute this observation to the severity of the associated refractory heart failure that necessitated such treatments. However, it is possible that these drugs can cause vasodilation in the pulmonary circulation, where regional blood flow becomes even more diverted to the unobstructed areas, thus causing more ischemia in the subpleural areas beyond the emboli and increasing the likelihood of pulmonary infarcts there.¹¹⁵

Figure 4. How hypoxemia occurs from low V/Q (ventilation/perfusion ratio) in the lung, mainly because of its low numerator (V), and how it can be intuitively correlated with infiltrates on chest X-ray (CXR), e.g., from pus, water, blood, or proteinaceous materials.

Figure 5. How hypoxemia occurs from low V/Q (ventilation/perfusion ratio) in the lung, mainly because of its high denominator (Q), and how it could be counterintuitive in an unremarkable chest X-ray (CXR), if V is maintained.

PULMONARY HYPERTENSION (PH) IN APTE

PH occurs after APTE, as a result of the increased pulmonary vascular resistance (PVR), which is in turn due to the clot obstruction in the pulmonary vasculature and possibly the release of vasoactive mediators. Substances such as histamine,¹¹⁶ serotonin,^{117,118} thrombin,¹¹⁹ prostaglandins,¹²⁰ and the endothelins¹²¹ have all been implicated. The observation that PH following APTE correlates poorly with embolic load¹²² supports their roles. It is reasonable to suggest that the differing patterns of their release, in both timing and intensity,^{123,124} may partly account for the variations in the resulting pulmonary hemodynamics. However, others have asserted that the change in PVR was essentially the result of mechanical obstruction and have ruled out changes in pulmonary vascular tone, as suggested in a Starling model.¹²⁵ Research in this field became even more complicated because many concomitant variables that could confound the conclusions were not regularly reported, e.g., the degree of hypoxemia,¹²⁶ hematocrit,¹²⁷ Qt,¹²⁸ lung volume,^{129,130} fluid status, and time from onset.^{26,50} In this article, different views will be addressed, along with answering 5 additional questions to illustrate the controversies:

6. How should pulmonary vasoconstriction be estimated after APTE?
7. What is the temporal pattern of PH after APTE?
8. Does vasoconstriction also affect gas exchange after APTE?
9. Are vasodilator drugs harmful in the treatment of APTE?
10. Why does pulmonary arterial pressure (Ppa) usually reach a maximum of 40 Torr in healthy patients with APTE?

Pulmonary circulation is a low-pressure, high-flow system,¹³¹ with a vast cross-sectional area and a huge capacity for recruitment at higher flow.¹³²⁻¹³⁴ In order to estimate the contribution of pulmonary vasoconstriction following APTE, we presume that the increase in PVR can be roughly divided into two major components, i.e., the obstructive component due to presence of clots and the vasoconstrictive component due the release of mediators.

Endothelins,¹³⁵ which affect both bronchial and vascular tone in the lung, have been the focus of considerable interest in the pathogenesis in PH since their discovery. They are omnipresent in the lung, along with their receptors,^{136,137} and are thought to be the key mediators in many forms of vascular lung injury, such as

adult respiratory distress syndrome,^{138,139} primary¹⁴⁰ or secondary PH,¹⁴¹⁻¹⁴³ scleroderma,¹⁴⁴ sepsis,¹⁴⁵ air embolism,^{146,147} and APTE.^{121,148,149} Because of their potency and universal nature in regulating vascular smooth muscle tone, some have asserted that other mediators implicated in APTE, including thromboxane¹⁵⁰ and serotonin,¹⁵¹ manifest their vasoconstriction via the endothelin pathway.¹⁵²⁻¹⁵⁴ Lee et al.¹²¹ showed that endothelin-1 was expressed in situ in the embolized lung and that its antagonist mitigated the subsequent PH.

In a porcine model of APTE, two groups of animals were induced with APTE, and their hemodynamics were measured in parallel over time, with one group receiving endothelin antagonist infusion and the other serving as controls. Other potentially confounding physiological parameters, including Qt, PaO₂, PaCO₂, lung volume, fluid status, and hematocrit or blood viscosity, were all kept relatively constant during the experiment in the same group and between groups. More importantly, consistent embolic loads and embolic patterns were achieved by injecting uniform-sized preformed clots into the lung until Ppa was about twice baseline value within 10 minutes. Their similar embolic patterns were subsequently documented by regional blood flow data using FMSs. The results showed that in the first 2 hours after APTE, the obstructive component accounted for 75% of the increase in PVR, while the vasoconstrictive component steadily accounted for 25%, when the Ppa approximately doubled after embolic injury (Fig. 6).¹⁵⁵

ANSWERING THE 5 ADDITIONAL QUESTIONS

How should pulmonary vasoconstriction be estimated after APTE?

The animal models should mimic the clinical setting to be more relevant. Preferably, they would be set up in vivo with a closed chest, using minimal surgery and avoiding excessive vascular cannulation.¹⁵⁶ The premises of the models should not be based on heavy assumptions, nor should the conclusions be drawn from an arbitrary dichotomy between preset choices.^{125,157,158} Pigs should usually be chosen because of their stronger vascular reactivity to physiological stimuli such as hypoxemia.²⁷

Thromboemboli of standardized size and load,^{159,160} rather than glass or inert beads, should be used. The clots containing coagulation factors, e.g., thrombin, have inherent vasoactive properties, whereas the use of inert emboli compromises the purpose.¹²⁵ The pattern of embolization between groups should be documented by FMSs and post

Figure 6. Endothelin-mediated vasoconstrictive component after acute pulmonary thromboembolism (APTE) accounted for about 25% of the total increase in the pulmonary vascular resistance index (PVRI). Group 1 is the control group; group 2 received tezosentan (see text).

mortem markings¹⁵⁵ because it affects the obstructive component of PVR directly.

Animals of different sizes and species have different Qts and recruitable vascular beds in the lung. Since body weight (BW) is generally proportional to Qt, the normalization of Qt into cardiac index (CI, or Qt/BW) is preferred in the calculation of the PVR index: $PVRI = 80 \times (P_{pa} - P_w)/CI$, where P_w is pulmonary capillary wedge pressure.

Because APTE is a dynamic disease, time is an unavoidable factor in affecting pulmonary hemodynamics because of the recovery nature of regional blood flow toward the preembolized state. Therefore, the hemodynamics in both control and experimental (using pharmacological antagonist) groups must be measured at the same time points, and the FMS data at each time point must be recorded to document how the regional flow pattern changes over time. If the obstructive pattern by the emboli is significantly different between groups immediately after APTE, then the subsequent data become moot.

In order to estimate PVR after APTE, all relevant parameters must be held steady as much as possible to avoid their confounding effects. They include Qt, PaO_2 , $PaCO_2$, pH, hematocrit, and fluid status. Lung volume should be maintained throughout by mechanical ventilation and positive end-expiratory pressure. No vasopressor should be used. Thus, if one uses P_{pa} as the key parameter in drawing conclusions about PVR¹⁶¹ without taking

all the rest into considerations, the conclusion will be on questionable ground.

What is the temporal pattern of PH after APTE?

In our experiments, P_{pa} acutely increased as embolization began, and then it leveled off to a plateau level.¹⁵⁵ It did so after each additional load of clots, with the peak P_{pa} often exceeding 40 Torr temporarily, followed by a subsequent plateau below 40 Torr. These patterns were compatible with those of Smulders¹²⁴ The temporal profile of P_{pa} correlated well with the release timing of vasoactive mediators. Tsang et al.¹⁴⁸ reported a biphasic release of immunoreactive endothelins. These intense but short-lived increases in P_{pa} within minutes of APTE were likely due to a combination of severe initial vasoconstriction and the maximal impact of embolic obstruction prior to any accommodation of the pulmonary vasculature to the clots or their movement. Acute right ventricular failure occurred as a consequence of such a sudden increase in afterload, which resulted in paradoxical septal motion, leading to an abrupt compromise in left ventricular function. These chain reactions could have fatal consequences, often in the first hour if left untreated.¹⁶² Gradual accumulation of multiple pulmonary emboli in the lung would likely be better tolerated than the sudden arrival of a large one with the same total mass.

Does vascular tone affect gas exchange after APTE?

Previous investigation using a nonspecific endothelin antagonist to attenuate vasoconstriction did not show a beneficial effect on V-Q mismatch after APTE.¹⁶³ Actually, the data showed a negative trend toward a slower recovery of V/Q heterogeneity in the tezosentan treatment group, compared to controls. This was presumably due to the persistently higher flow to the unobstructed and vasodilated areas, where V/Q was already low. Thus, the relative vasodilatation under the influence of tezosentan compounded the V/Q heterogeneity and worsened gas exchange. In contrast, vasodilatation in locations beyond embolic obstruction could not allow more flow there as long as the existing clots were in place.

It has also been reported that potent vasodilators had an adverse effect on oxygenation in other forms of acute lung injury, e.g., adult respiratory distress syndrome¹⁶⁴ and obliterative PH.¹⁶⁵ Some researchers have suggested that maintaining pulmonary vascular tone could improve V-Q matching in these conditions and have advocated against mitigating the existing vascular tone by vasodilators. In order to decide whether potent vasodilators are use-

ful in a given setting, the systemic oxygen delivery must be obtained. First, do no harm.

Are vasodilator drugs harmful in the treatment of heart failure after APTE?

Yes. First, there are very few truly specific vasodilators for the pulmonary circulation. Many cause systemic hypotension and have minimal flow-independent effect, e.g., hydralazine, nitroprusside, and even dobutamine.^{166,167} Second, if patients are either underfilled or have ventricular septal shift, using this class of drugs causes more harm than good and complicates fluid therapy, not to mention the decreased coronary perfusion in a hypotensive state. The more relevant resuscitation end points are optimal Qt and systemic blood pressure, rather than Ppa per se. Third, some vasodilators have been shown to increase the risk of pulmonary infarcts.¹¹⁵

Recent study has suggested that epoprostenol did not change right ventricular diameter in patients with APTE. However, these measurements were somewhat indirect in relation to the primary end points, such as Qt and systemic blood pressure. Transthoracic echocardiogram estimation of right ventricular size and flow were not as precise as those for the left ventricle.¹⁶⁸ Nevertheless, there was no benefit.

Why does pulmonary arterial pressure (Ppa) generally reach a maximum of 40 Torr in healthy patients with APTE?

It has often been observed that among otherwise healthy patients suffering from APTE, Ppa rarely exceeds 40 Torr.^{169,170} This phenomenon is usually explained by the fact that the thin-walled right ventricle (RV) cannot suddenly generate sufficient pressure on demand to overcome the increased afterload. On the other hand, patients with previous cor pulmonale can do so because their muscular RV is hypertrophied over time.

However, there is another consideration. Pulmonary circulation, with its normally large cross-sectional area, can readily accommodate increased flow in many regions. Thus, this large reserve capacity can attenuate the rise in Ppa by progressively recruiting more and more vasculature. In healthy subjects suffering from APTE, this recruitment will be limited to the nonembolized regions, but the reserve is usually still sufficient. Consequently, Ppa reaches a certain limit, say 40 Torr, only because any further increase in Ppa is mitigated by further increases in recruitment, either by distension or by opening of the previously closed vessels as the critical opening pressure is reached. On the other hand, if Qt is so low during shock from a

large embolic load, Ppa will not be high, in accordance with the Poiseuille Law.

In addition, if the patient has a significant reduction of recruitment potential due to the loss of pulmonary vasculature, e.g., emphysema,¹⁷¹ the Ppa can reach a higher level after APTE. Similarly, in patients with mitral stenosis or congestive heart failure, their fully recruited pulmonary vasculature becomes stiffer, and their Ppa also can go even higher than 40 Torr when some regional flow is increased after APTE.³⁴

CONCLUDING REMARKS

The remarkable variability of hypoxemia in APTE is explained by the differing embolic sizes, loads, and 3D locations that result in an infinite pattern of regional blood flow diversion and V/Q heterogeneity. Two key physiological principles account for the subsequent hypoxemia, i.e., (1) low-V/Q units are created by the increase in the denominator of that ratio, or Q, in the less embolized areas, and (2) PaO₂ is extraordinarily sensitive to any decrease in V/Q between 1 and 0, to the extent that this same change exceeds that when V/Q decreases from infinity to 1. It is further confounded by the concomitant Qt and a patient's preexisting cardiopulmonary status. Generally speaking, pulmonary edema and occasional atelectasis are minor contributing factors, while incidental anatomical shunts are relevant only in some cases. Ideas involving baroreceptor, surfactant, ventilator control, and red blood cell transit time are speculative. Ventilation shift within the embolized lung mediated via hypocapnic bronchoconstriction is a homeostatic mechanism but generally does not affect oxygenation much.

In terms of pulmonary hemodynamics after APTE, the lack of vascular accommodation and severe pulmonary vasoconstriction immediately after APTE explains the disproportionately high PVR and shock among some patients during the early phase, leading to their higher mortality in the first hour. It subsides to a steadier but still significant level afterward. Endothelin-mediated vasoconstriction accounts for about 25% of the total increase in PVR. Unfortunately, the literature on this topic is confusing, because of the variable experimental designs, use of inert embolic materials, invasive animal preparations, and neglect of controlling for time in this dynamic disease. Any use of vasodilators in treating PH must be discouraged, as they can do more harm than good. Patients have died of obstructive shock, and definitive relief is achieved by timely anticoagulation or judicious thrombolysis. The value of Ppa by itself is not prognostic, unless it is interpreted with other key data, such as Qt.

This update is made possible by the tremendous contributions by many pioneers in the field. Reflecting on Dr. Robin's comment at the beginning of the article, readers can draw their own conclusions as to whether the emperor finally has got some new clothes. Much remains to be learned.

APPENDIX

O₂-CO₂ DIAGRAM

In this diagram (Fig. A1), PO₂ and PCO₂ are plotted on the X- and Y-axes, respectively, and they represent the alveolar gas composition while breathing room air at all possible V/Q ratios, from 0 to infinity. The gray V/Q line is schematically drawn to illustrate the underlying concept and is not intended to be mathematically precise.

Generally speaking, at a given percentage of inspired oxygen and a given venous gas composition, i.e., PvO₂ and PvCO₂, a ventilation-perfusion (V/Q) line can be drawn for all alveoli that can exist in the lung, with V/Q ranging from 0 (point V) to infinity (point I). It is based on the assumption that diffusion is complete between alveolar gases and capillary and arterial blood (P_AO₂ = P_cO₂ = P_aO₂ and P_ACO₂ = P_cCO₂ = P_aCO₂). The exchange ratio (*R*) is defined as the ratio of the change in CO₂ content to the change in O₂ content, or $R = \Delta C_{CO_2} / \Delta C_{O_2}$. The V/Q line is constructed as the intersection points of all *R* values, where gas *R* = blood *R*, in each case. This is true because at that intersection point and in a steady state,

the same content of oxygen is removed from the alveolar gas and added to the blood, and vice versa for CO₂.^{28,29} The shape of the line is also determined by the O₂- and CO₂-hemoglobin dissociation curves, which are affected by the Bohr and Haldane effects, respectively.⁴¹

The V/Q equation is derived as follows. The amount of CO₂ removed from the alveolar gas per minute is

$$VCO_2 = V \times P_A CO_2 \times K, \quad (A1)$$

where the inspired gas contains no CO₂, *V* is the expired alveolar ventilation, and *K* is constant. The amount of CO₂ taken from the capillary blood per minute is

$$VCO_2 = Q \times (C_v CO_2 - C_a CO_2), \quad (A2)$$

where *Q* is flow and C_vCO₂ and C_aCO₂ are contents of CO₂ in venous and arterial blood (in vol%), respectively. Thus, in a steady state, these two equations are equivalent, or

$$\frac{V}{Q} = \frac{8.63 \times (C_v CO_2 - C_a CO_2)}{P_A CO_2} \quad (A3)$$

at 37°C and under BTPS (body temperature and pressure, saturated), SPTD (standard temperature and pressure, dry) conditions.

The value of *R* can be calculated with the following equation,

Figure A1. O₂-CO₂ diagram in room air. As the V/Q (ventilation/perfusion ratio) increases from the mixed venous point (V), where V/Q = 0, to the inspired gas point (I) where V/Q = ∞, the PO₂ and PCO₂ of these gas exchange units move rightward and downward, respectively, along the gray V/Q line.

$$R = \frac{\Delta C_{CO_2}}{\Delta C_{O_2}} = \frac{CvCO_2 - CaCO_2}{CaO_2 - CvO_2}, \quad (A4)$$

where C is the gas content. If CvO_2 and $CvCO_2$ are known, then a trial-and-error method can be used to estimate CaO_2 and $CaCO_2$ simultaneously by moving up and down the R lines. Once the corresponding partial pressures, i.e., PaO_2 and $PaCO_2$, are known, V/Q can be obtained, eventually for all R ,³⁰ with equation (A3). The other traditional method of solving is more precise but cumbersome.

There are three important points on the graph (Fig. A1) described for room air. The first is the normal alveolar gas composition at $PaO_2 = 100$ Torr and $PaCO_2 = 40$ Torr. For all practical purposes, they are the same as PaO_2 and $PaCO_2$ in arterial blood (point a). The second is the mixed-venous-blood point (V), where $PvO_2 = 40$ Torr and $PvCO_2 = 46$ Torr. The V/Q ratio is 0, or shunt, in which no ventilation occurs. The third is the moist-inspired-gas point (I), where $PiO_2 = 150$ Torr, or $0.21 \times (760 - 47)$ Torr, and $PiCO_2 = 0$ Torr. The V/Q ratio is ∞ , i.e., no perfusion. The shape of the graph will be elongated if the percentage of inspired oxygen is increased as point I moves to the right.

It is important to point out that as the line moves leftward from point a to point V, slight changes in V/Q from 0.86 to 0 in this flat portion can result in dramatic reduction of PaO_2 but little change in $PaCO_2$. The physiological margin for hypoxemia at this low range is exquisitely small. Any decrease in ventilation or increase in perfusion without compensation by the other parameter can result in significant hypoxemia.

On the other hand, as the line moves rightward and downward from a to I, significant decreases in $PaCO_2$ and modest increases in PaO_2 are seen. The gain in PaO_2 at higher V/Q (>1), however, does not result in a meaningful increase in oxygen content, as the oxygen saturation there is already near 100% and the plasma solubility of oxygen is poor. Thus, in cases where there is considerable V/Q heterogeneity, the created high- V/Q units cannot compensate for the low- V/Q units in mitigating hypoxemia because of the sigmoid shape of the hemoglobin-oxygen dissociation curve and the low weighing factor (Q) in the determination of composite arterial blood O_2 saturation. Consequently, increased alveolar arterial oxygen gradient can be expected.

To illustrate the construction of the V/Q line, a gas exchange value of 0.8 is used as an example. In Figure A1, the R line for gas (or slope = 0.8 in absolute value) and the blood R line at $R = 0.8$ are drawn. Relevant isopleths for

O_2 and CO_2 contents in vol% are shown. Hemoglobin = 14 g%.

For the gas R line, in which gas partial pressure is linearly proportional to gas content,

$$R = \frac{\Delta C_{CO_2}}{\Delta C_{O_2}} = \frac{\Delta P_{ACO_2}}{\Delta P_{AO_2}} = \frac{P_{ACO_2} - P_{ICO_2}}{P_{IO_2} - P_{AO_2}} = \frac{40 - 0}{150 - 100} = 0.8.$$

For the blood R line, in which blood partial pressure is not linearly proportional to blood content,

$$R = \frac{\Delta C_{CO_2}}{\Delta C_{O_2}} = \frac{C_{vCO_2} - C_{aCO_2}}{C_{aO_2} - C_{vO_2}} = \frac{52 - 48}{19.5 - 14.5} = 0.8.$$

The isopleths for O_2 and CO_2 content are drawn to show the values used in the calculations, and their shapes are affected by the Bohr and Haldane effects, respectively. At point a, where the two lines intersect, or the gas R line meets the blood R line with the same value of 0.8, $V/Q = 8.63 \times (52 - 48)/40 = 0.863$, using equation (A3).

ACKNOWLEDGMENTS

We thank Mr. Wayne Lamm, at the University of Washington, for his insights in the preparation of the manuscript.

Source of Support: We thank the British Columbia Heart and Stroke Foundation and the British Columbia Lung Association for their grant support.

Conflict of Interest: None declared.

REFERENCES

1. Robin ED. Overdiagnosis and overtreatment of pulmonary embolism: the emperor may have no clothes. *Ann Intern Med* 1977;87:775–781.
2. Secker-Walker RH. On purple emperors, pulmonary embolism and venous thrombosis. *Ann Intern Med* 1983;98:1006–1008.
3. Goldhaber S. Pulmonary embolism. *N Engl J Med* 1998;339:93–104.
4. Wood KE. Major pulmonary embolism. *Chest* 2002;121:877–905.
5. Tapson VF. Acute pulmonary embolism. *N Engl J Med* 2008;358:1037–1052.
6. Elliott CG. Pulmonary physiology during pulmonary embolism. *Chest* 1992;101(suppl.):163S–171S.
7. Sasahara AA, Cannilla JE, Morse RL, Sidd JJ, Tremblay GM. Clinical and physiologic studies in pulmonary thromboembolism. *Am J Cardiol* 1967;20:10–20.
8. Robin ED, McCauley RF. The diagnosis of pulmonary embolism: when will we ever learn? *Chest* 1995;107:3–4.
9. Blackmon JR, Sautter RD, Wagner HN, Sasahara, A, and trial committees. The urokinase pulmonary embolism trial:

- associated clinical and laboratory findings. *Circulation* 1973; 47(suppl. II):81–85.
10. Baird JS, Greene A, Schleien CL. Massive pulmonary embolus without hypoxemia. *Pediatr Crit Care Med* 2005;6: 602–603.
 11. Wilson JE III, Pierce AK, Johnson RL Jr, Wingo ER, Harell WR, Curry GC, Mullins CB. Hypoxemia in pulmonary embolism, a clinical study. *J Clin Invest* 1971;50:481–491.
 12. Santolucando A, Prediletto R, Fornai E, Formichi B, Begliomini E, Giannella-Neto A, Giuntini C. Mechanisms of hypoxemia and hypocapnia in pulmonary embolism. *Am J Respir Crit Care Med* 1995;152:336–347.
 13. Malik AB, van der Zee H. Time course of pulmonary vascular response to microembolization. *J Appl Physiol* 1977; 43:51–58.
 14. Freitas JE, Sarosi MG, Nagle CC, Yeomans ME, Freitas AE, Juni JE. Modified PIOPED criteria used in clinical practice. *J Nucl Med* 1995;36:1573–1578.
 15. Worsley DF, Alavi A. Comprehensive analysis of the results of the PIOPED study. *J Nucl Med* 1995;36:2380–2387.
 16. Burton G, Seed W, Vernon P. Observations on the mechanism of hypoxemia in acute minor pulmonary embolism. *Br Med J* 1984;289:705–712.
 17. Tsang JY, Graham MM, Robertson HT. The effects of norepinephrine on gas exchange and regional blood flow after massive bead embolization. *J Crit Care* 1990;5:180–185.
 18. Tsang J, Middaugh M, Emery M, Hlastala M. Gas exchange and regional redistribution of pulmonary blood flow during resuscitation of acute pulmonary bead embolization. *Pulm Pharmacol* 1992;5:273–278.
 19. Bauman G, Lützen U, Ullrich M, Gaass T, Dinkel J, Elke J, Meybohm P, et al. Pulmonary functional imaging: qualitative comparison of Fourier decomposition MR imaging with SPECT/CT in porcine lung. *Radiology* 2011;260:551–559.
 20. Robertson H, Glenny R, Stanford D, McInnes L, Luchtel D, Covert D. High-resolution maps of regional ventilation utilizing inhaled fluorescent microspheres. *J Appl Physiol* 1997;82:943–953.
 21. Schimmel C, Frazer D, Glenny RW. Extending fluorescent microsphere methods for regional blood flow to 13 simultaneous colors. *Am J Physiol Heart Circ Physiol* 2001; 280:H2496–H2506.
 22. Glenny R, Bernard S, Brinkley M. Validation of fluorescent-labelled microspheres for measurement of regional organ perfusion. *J Appl Physiol* 1993;4:2585–2597.
 23. Altemeier W, Robertson H, Glenny R. Pulmonary gas exchange analysis by using simultaneous deposition of aerosolized and injected microspheres. *J Appl Physiol* 1998; 85:2344–2351.
 24. Tsang J, Lamm W, Starr I, Hlastala M. Spatial pattern of ventilation-perfusion mismatch following acute pulmonary thromboembolism in pigs. *J Appl Physiol* 2005;99: 662–669.
 25. Manier G, Castaing Y. Gas exchange abnormalities in pulmonary vascular and cardiac diseases. *Thorax* 1994;49: 1169–1174.
 26. D'Alonzo GE, Dantzker DR. Gas exchange alterations following pulmonary thromboembolism. *Clin Chest Med* 1984; 5:411–419.
 27. Peake MD, Harabin AL, Brennan NJ, Sylvester JT. Steady-state vascular responses to graded hypoxia in isolated lungs of five species. *J Appl Physiol* 1981;51:1214–1219.
 28. Rahn H, Fenn WO. Representation of blood gases on O₂-CO₂ diagram. In: A graphic analysis of the respiratory gas exchange: the O₂-CO₂ diagram. Washington DC: American Physiological Society, 1956:13–18.
 29. Riley RL, Cournand A. Ideal alveolar air and the analysis of ventilation perfusion relationships in the lungs. *J Appl Physiol* 1949;1:825–847.
 30. West JB. How to talk the V/Q language. In: Ventilation/ blood flow and gas exchange. 4th ed. Oxford, Blackwell Scientific, 1985:31–79, 109–113.
 31. Altemeier WA, Robertson HT, McKinney S, Glenny RW. Pulmonary embolization causes hypoxemia by redistributing regional blood flow without changing ventilation. *J Appl Physiol* 1998;85:2337–2343.
 32. Tsang JY, Frazer D, Hlastala MP. Ventilation heterogeneity does not change following pulmonary microembolism. *J Appl Physiol* 2000;88:705–712.
 33. Dantzker DR, Bower JS. Clinical significance of pulmonary function tests: alterations of gas exchange following pulmonary thromboembolism. *Chest* 1982;81:495–501.
 34. Sharma GVRK, McIntyre KM, Sharma S, Sasahara AA. Clinical and hemodynamic correlates in pulmonary embolism. *Clin Chest Med* 1984;5:421–437.
 35. Manier G, Castaing Y. Influence of cardiac output on oxygen exchange in acute pulmonary embolism. *Am Rev Respir Dis* 1992;145:130–136.
 36. Tsang JY, Lamm WJE, Neradilek B, Polissar NL, Hlastala MP. The unpredictable effect of changing cardiac output on hypoxemia after acute pulmonary thromboembolism. *Clin Med Circ Respir Pulm Med* 2008;2:73–84.
 37. Jardin F, Gurdjian F, Desfonds P, Fouilladieu JL, Margairaz A. Hemodynamic factors influencing arterial hypoxemia in massive pulmonary embolism with circulatory failure. *Circulation* 1979;59:909–912.
 38. Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H, Perrier A. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. *Ann Intern Med* 2006;144:165–171.
 39. Anderson F, Wheeler H. Venous thromboembolism, risk factors and prophylaxis. *Clin Chest Med* 1995;16:235–251.
 40. Wagner PD, Dantzker DR, Dueck R, Clausen L, West JB. Ventilation perfusion inequality in chronic obstructive pulmonary disease. *J Clin Invest* 1977;59:203–216.
 41. Hlastala MP, Berger AJ. Blood gas transport and tissue gas exchange. In: Physiology of respiration. New York: Oxford University Press, 1996:94–113.
 42. Ambrosetti M, Ageno W, Spanevello A, Salerno M, Pedretti RFE. Prevalence and prevention of venous thromboembolism in patients with acute exacerbation of COPD. *Thromb Res* 2003;112:203–207.
 43. Lippmann M, Fein A. Pulmonary embolism in the patient with chronic obstructive pulmonary disease. *Chest* 1981;79:39–42.
 44. Lesser BA, Leeper KV Jr, Stein PD, Saltzman HA, Chen J, Thompson BT, Hales CA, Popovich J, Greenspan RH, Weg JG. The diagnosis of acute pulmonary embolism in patients with chronic obstructive pulmonary diseases. *Chest* 1992;102:17–22.

45. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine and N-acetylcysteine for pulmonary fibrosis. *N Engl J Med* 2012;366:1968–1977.
46. Mariell J, Brozena S. Heart failure. *N Engl J Med* 2003;348:2007–2018.
47. Tomashefski JF, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome. *Am J Pathol* 1983;112:112–126.
48. Donahoe M. Acute respiratory distress syndrome: a clinical review. *Pulm Circ* 2011;1:192–211.
49. Angus DC, van der Poll T. Severe sepsis and septic shock. *N Engl J Med* 2013;369:840–851.
50. Dantzker DR, Wagner PD, Tornabene VW, Alazraki NP, West JB. Gas exchange after pulmonary thromboembolism in dogs. *Circ Res* 1978;42:92–103.
51. Ehrhart IC, Granger WM, Hofman WF. Effect of arterial pressure on lung capillary pressure and edema after microembolism. *J Appl Physiol* 1986;60:133–140.
52. Weisberg H, Lopez JF, Luria MH, Katz LN. Persistence of lung edema and arterial pressure rise in dogs after lung emboli. *J Appl Physiol* 1964;641–646.
53. Tsang J, Brush B. Lung water is increased in regions of higher neutrophil retention after acute bead embolization. *J Appl Physiol* 1996;80:1513–519.
54. Stein PD, Terrin ML, Hales CA, Palevsky HI, Saltzman HA, Thompson BT, Weg JG. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. *Chest* 1991;100:598–603.
55. Miller GA, Sutton GC. Acute massive pulmonary embolism: clinical and hemodynamic findings in 23 patients studied by cardiac catheterization and pulmonary arteriography. *Br Heart J* 1970;32:518–523.
56. Konstantinides S, Geibel A, Kasper W, Olschewski M, Blumel L, Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. *Circulation* 1998;97:1946–1951.
57. Lovering AT, Stickland MK, Kelso AJ, Eldridge MW. Direct demonstration of 25- and 50- μ m arteriovenous pathways in healthy human and baboon lungs. *Am J Physiol Heart Circ Physiol* 2007;292:H1777–H1781.
58. Lovering AT, Romer LM, Haverkamp HC, Pegelow DF, Hokanson JS, Eldridge MW. Intrapulmonary shunting and pulmonary gas exchange during normoxic and hypoxic exercise in healthy humans. *J Appl Physiol* 2008;104:1418–1425.
59. Stickland MK, Lovering AT, Eldridge MW. Exercise-induced arteriovenous intrapulmonary shunting in dogs. *Am J Respir Crit Care Med* 2007;176:300–305.
60. Stein PD, Willis PWI, DeMets DL. Plain chest roentgenogram in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. *Am J Noninvasive Cardiol* 1987;1:171–176.
61. Cvitanic O, Marino PL. Improved use of arterial blood gas analysis in suspected pulmonary embolism. *Chest* 1980;95:48–51.
62. Bouchama A, Curley W, Al-Dossary S, Elguindi A. Refractory hypercapnia complicating massive pulmonary embolism. *Am Rev Respir Dis* 1988;138:466–468.
63. Laks MM, Juratsch CE, Garner D, Beazell J, Criley JM. Acute pulmonary artery hypertension produced by distention of the main pulmonary artery in the conscious dog. *Chest* 1975;68:807–813.
64. Coleridge JCG, Kidd C. Electrophysiological evidence of baroreceptors in the pulmonary artery of the dog. *J Physiol* 1960;150:319–331.
65. Chernick V, Hodson WA, Greenfield LJ. Effect of chronic pulmonary artery ligation on pulmonary mechanics and surfactant. *J Appl Physiol* 1966;21:1315–1320.
66. Finley TH, Swenson EW, Clements JA, Gardner RE, Wright RR, Severinghaus JW. Changes in mechanical properties, appearance and surface activities of extracts of one lung following occlusion of its pulmonary artery in the dog. *Physiologist* 1960;3:56–72.
67. Kafer ER. Respiratory function in pulmonary thromboembolic disease. *Am J Med* 1969;47:904–915.
68. Colp C, Williams MH Jr. Pulmonary function following pulmonary embolization. *Am Rev Respir Dis* 1962;85:799–807.
69. Tsang JY, Montaner JSG, Hogg JC. Effects of pulmonary edema on regional blood volume and red blood cell transit time. *J Clin Invest* 1986;77:1780–1785.
70. Weibel ER. Pulmonary diffusing capacity: morphometry. In: *The pathway for oxygen: structure and function in the mammalian respiratory system*. Cambridge, MA: Harvard University Press, 1984:347–358.
71. Weibel ER. Lung cell biology. In: Fishman AP, ed. *Handbook of physiology*. Sect. 3: The respiratory system. Vol. 1: Circulation and nonrespiratory functions. 3rd ed. Baltimore: American Physiological Society, 1985:63–65.
72. Hatle L, Rokseth R. The arterial to end-expiratory carbon dioxide tension gradient in acute pulmonary embolism and other cardiopulmonary diseases. *Chest* 1974;66:352–357.
73. Burki NK. The dead space to tidal volume ratio in the diagnosis of pulmonary embolism. *Am Rev Respir Dis* 1986;133:679–685.
74. Allgood RJ, Wolfe WG, Ebert PA, Sabiston DC Jr. Effects of carbon dioxide on bronchoconstriction after pulmonary artery occlusion. *Am J Physiol* 1968;214:772–775.
75. Swenson EW, Finley TN, Guzman SV. Unilateral hypoventilation in man during temporary occlusion of one pulmonary artery. *J Clin Invest* 1961;40:828–835.
76. Severinghaus JW, Swensen EW, Finley TN, Lategola MT, Williams J. Unilateral hypoventilation produced in dogs by occluding one pulmonary artery. *J Appl Physiol* 1961;6:53–60.
77. DeAngelo E, Caldirini IS, Tavola M. The effects of CO₂ on respiratory mechanics in anaesthetized paralysed human. *Anaesthesiology* 2001;94:604–610.
78. Emery MJ, Eveland RL, Kim SS, Hildebrandt J, Swensen ER. CO₂ relaxes parenchyma in the liquid-filled rat lung. *J Appl Physiol* 2007;103:710–716.
79. Swenson ER, Graham MM, Hlastala MP. Acetazolamide slows $\dot{V}_A/\dot{Q}$ matching after changes in regional blood flow. *J Appl Physiol* 1995;78:1312–1318.
80. Nadel JA, Colebatch HJH, Olsen CR. Location and mechanism of airway constriction after barium sulfate microembolism. *J Appl Physiol* 1964;19:387–394.
81. Levy S, Simmons D. Redistribution of alveolar ventilation following pulmonary thromboembolism in the dog. *J Appl Physiol* 1974;36:60–68.
82. Tsang JY, Lamm WJE, Swenson ER. Regional CO₂ tension quantitatively mediates homeostatic redistribution of

- ventilation following acute pulmonary thromboembolism in pigs. *J Appl Physiol* 2009;107:755–762.
83. Mitzner W, Sylvester JT. Hypoxic vasoconstriction and fluid filtration in pig lungs. *J Appl Physiol* 1981;51:1065–1071.
 84. Sylvester JT, Mitzner W, Ngeow Y, Permutt S. Hypoxic constriction of alveolar and extra-alveolar vessels in isolated pig lungs. *J Appl Physiol* 1983;54:1660–1666.
 85. Hull RD, Hirsh J, Carter CJ, Raskob GE, Gill GJ, Jay RM, Leclerc JR, David M, Coates G. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. *Chest* 1985;88:819–828.
 86. Kumar AM, Parker JA. Ventilation/perfusion scintigraphy. *Emerg Med Clin N Am* 2001;19:957–973.
 87. Manganelli D, Palla A, Donnamaria V, Giuntini C. Clinical features of pulmonary embolism: doubts and certainties. *Chest* 1995;107(1 suppl.):25S–32S.
 88. Palla A, Petruzzelli S, Donnamaria V, Giuntini C. The role of suspicion in the diagnosis of pulmonary embolism. *Chest* 1995;107(1 suppl.):21S–24S.
 89. D'Alonso GE, Bower JS, DeHart P, Dantzker DR. The mechanisms of abnormal gas exchange in acute massive pulmonary embolism. *Am Rev Respir Dis* 1983;128:170–172.
 90. Delcroix M, Mélot C, Vermeulen F, Naeije R. Hypoxic pulmonary vasoconstriction and gas exchange in acute canine pulmonary embolism. *J Appl Physiol* 1996;80:1240–1248.
 91. Morpurgo M, Schmid C. The spectrum of pulmonary embolism, clinicopathologic correlations. *Chest* 1995;107(1 suppl.):18S–20S.
 92. Oser RF, Zukerman DA, Gutierrez FR, Brink JA. Anatomic distribution of pulmonary emboli at pulmonary angiography: implications for cross-sectional imaging. *Radiology* 1996;199:31–35.
 93. Scott JA. The lung scan and the abnormal chest X-ray: difficult diagnosis. *Nucl Med Commun* 2004;25:1137–1141.
 94. Stein PD, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, et al. Multidetector computed tomography for acute pulmonary embolism. *N Eng J Med* 2006;354:2317–2327.
 95. Breen P, Schumacker P, Hedenstierna G, Ali J, Wagner P, Wood L. How does increased cardiac output increase shunt in pulmonary edema? *J Appl Physiol* 1982;53:1273–1280.
 96. Tsang J, Baile E, Hogg J. Relationship between regional pulmonary edema and blood flow. *J Appl Physiol* 1986;60:449–457.
 97. Mélot C, Hallemans R, Naeije R, Mols P, Lejeune P. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1984;130:612–616.
 98. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. *Am J Cardiol* 1971;28:288–294.
 99. Marshall C, Marshall B. Site and sensitivity for stimulation of hypoxic pulmonary vasoconstriction. *J Appl Physiol* 1983;55:711–716.
 100. West JB, Dollery CT, Naimark A. Distribution of blood flow in isolated lung: relation to vascular and alveolar pressures. *J Appl Physiol* 1964;19:713–724.
 101. Permutt S, Riley RL. Hemodynamics of collapsible vessels with tone: the vascular waterfall. *J Appl Physiol* 1963;18:924–932.
 102. Hughes JMB, Glazier JB, Maloney JE, West JB. Effect of lung volume on the distribution of pulmonary blood flow in man. *Respir Physiol* 1968;4:58–72.
 103. Hakim TS, Lisbona R, Dean GW. Gravity-independent inequality in pulmonary blood flow in humans. *J Appl Physiol* 1987;63:1114–1121.
 104. Mitzner W, Chang HK. Hemodynamics of the pulmonary circulation. In: Chang HK, Paiva M, eds. *Respiratory physiology: an analytical approach*. New York: Marcel Dekker, 1989:561–602.
 105. Taihai MH, Nash MP, Lin CL, Hoffman EA. Supine and prone differences in regional lung density and pleural pressure gradients in the human lung with constant shape. *J Appl Physiol* 2009;107:912–920.
 106. Hopkins SR, Henderson AC, Levin DL, Yamada K, Arai T, Buxton RB, Prisk GK. Vertical gradients in regional lung density and perfusion in the supine human lung: the slinky effect. *J Appl Physiol* 2007;103:240–248.
 107. Glennly, R, Polissar N, McKinney S, Robertson HT. Temporal heterogeneity of regional pulmonary perfusion is spatially clustered. *J Appl Physiol* 1995;79:986–1001.
 108. Hakim TS, Michel RP, Chang HK. Partitioning of pulmonary vascular resistance in dogs by arterial and venous occlusion. *J Appl Physiol* 1982;52:710–715.
 109. Linehan JH, Dawson CA, Rickaby DA. Distribution of vascular resistance and compliance in a dog lung lobe. *J Appl Physiol* 1982;53:158–168.
 110. Linehan JH, Dawson CA. A three-compartment model of the pulmonary vasculature: effects of vasoconstriction. *J Appl Physiol* 1983;55:923–928.
 111. Wagnevoort CA. Pathology of pulmonary thromboembolism. *Chest* 1995;107:10S–17S.
 112. Dalen JE, Haffajee CI, Alpert JS, Howe JP III, Ockene IS, Paraskos JA. Pulmonary embolism, pulmonary hemorrhage and pulmonary infarction. *N Eng J Med* 1977;296:1431–1435.
 113. Tsao MS, Schraufnagel D, Wang NS. Pathogenesis of pulmonary infarction. *Am J Med* 1982;72:599–606.
 114. Parker BM, Smith JR. Pulmonary embolism and infarction. *Am J Med* 1958;24:402–427.
 115. Schraufnagel DE, Tsao MS, Yao YT, Wang NS. Factors associated with pulmonary infarction: a discriminant analysis study. *Am J Clin Pathol* 1985;84:15–18.
 116. Tucker A, Weir EK, Reeves JT, Grover RF. Pulmonary microembolism: attenuated pulmonary vasoconstriction with prostaglandin inhibitors and anti-histamines. *Prostaglandins* 1976;11:31–41.
 117. Huval WV, Mathieson MA, Stemp LI, Dunham BM, Jones AG, Shepro D, Hechtman HB. Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism. *Ann Surg* 1983;197:220–225.
 118. McGoon MD, Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. *J Clin Invest* 1984;74:828–833.
 119. Ferro TJ, Malik AB. Mechanisms of lung vascular injury and edema after pulmonary microembolism. *J Crit Care* 1989;4:118–126.

120. Todd MH, Cragg DBJ, Forrest JB, Ali M, McDonald JWD. The involvement of prostaglandins and thromboxanes in the response to pulmonary embolism in anaesthetized rabbits and isolated perfused lungs. *Thromb Res* 1983;30:81–90.
121. Lee J, Chun Y, Lee I, Tudor R, Hong S, Shim T, et al. Pathogenic role of endothelin 1 in hemodynamic dysfunction in experimental acute pulmonary thromboembolism. *Am J Respir Crit Care Med* 2001;164:1282–1287.
122. McIntyre KM, Sasahara AA. Determinants of right ventricular function and hemodynamics after pulmonary embolism. *Chest* 1974;65:534–543.
123. Smulders YM. Pathophysiology and treatment of hemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. *Cardiovasc Res* 2000;48:23–33.
124. Smulders YM. Contribution of pulmonary vasoconstriction to hemodynamic instability after acute pulmonary embolism: implications for treatment? *Neth J Med* 2001;58:241–247.
125. Mélot C, Delcroix M, Closset J, Vanderhoeft P, Lejunne P, Leeman M, Naeije R. Starling resistor vs. distensible vessel models for embolic pulmonary hypertension. *Am J Physiol Heart Circ Physiol* 1995;268:H817–H827.
126. Mitzner W. Resistance of the pulmonary circulation. *Clin Chest Med* 1983;4:127–137.
127. Julien M, Hakim TS, Vahi R, Chang HK. Effect of hematocrit on vascular pressure profile in dog lungs. *J Appl Physiol* 1985;58:743–748.
128. Krenz GS, Dawson CA. Flow and pressure distributions in vascular networks consisting of distensible vessels. *Am J Physiol Heart Circ Physiol* 2003;284:H2192–H2203.
129. Hakim TS, Michel RP, Chang HK. Effect of lung inflation on pulmonary vascular resistance by arterial and venous occlusion. *J Appl Physiol* 1982;53:1110–1115.
130. Mitzner W, Wagner EM. Pulmonary and bronchial vascular resistance. In: Scharf SM, Cassidy SS, eds. *Heart-lung interactions in health and diseases*. New York: Marcel Dekker, 1989:45–65.
131. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systemic review. *Eur Respir J* 2008;34:888–894.
132. Mélot C, Naeije R. Pulmonary vascular diseases. In: Roca J, Rodriguez-Roisin J, Wagner PD, eds. *Pulmonary and peripheral gas exchange in health and disease*. New York: Marcel Dekker, 2000:285–302.
133. Fung YC, Sobin SS. Elasticity of the pulmonary alveolar sheet. *Circ Res* 1972;30:451–469.
134. Graham R, Skoog C, Oppenheimer L, Rabson J, Goldberg HS. Critical closure in the canine pulmonary vasculature. *Circ Res* 1982;50:566–572.
135. Battistini B, Dussault P. Biosynthesis, distribution and metabolism of endothelins in the pulmonary system. *Pulm Pharmacol Therapeut* 1998;11:79–88.
136. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. *Circulation* 1996;94:1578–1584.
137. Sato K, Oka M, Hasunuma K, Ohnishi M, Sato K, Kira S. Effects of separate and combined ET_A and ET_B blockade on ET-1 induced constriction in perfused rat lungs. *Am J Physiol Lung Cell Mol Physiol* 1995;13:L668–L672.
138. Michael J, Markewitz B. Endothelins and the lung. *Am J Respir Crit Care Med* 1996;54:555–581.
139. Comellas AP, Briva A. Role of endothelin-1 in acute lung injury. *Transl Res* 2009;153:263–271.
140. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. *N Engl J Med* 1993;328:1732–1739.
141. Celik G, Karabiyikoglu G. Local and peripheral plasma endothelin-1 in pulmonary hypertension secondary to chronic obstructive pulmonary disease. *Respiration* 1998;65:289–294.
142. Cacoub P, Dorent R, Maistre G, Nataf P, Carayon A, Piette JC, Godeau P, Cabrol C, Gandjbakhch I. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. *Am J Cardiol* 1993;71:448–450.
143. Vachiéry JL, Davenport A. The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses. *Eur Respir Rev* 2009;18:260–271.
144. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, du Bois RM, Black CM. Increased levels of endothelin-1 and different endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. *Am J Pathol* 1997;151:831–841.
145. Snapper JR, Thabes JS, Lefferts PL, Lu W. Role of endothelin in endotoxin-induced sustained pulmonary hypertension in sheep. *Am J Respir Crit Care Med* 1998;157:81–88.
146. Simon M, Battistini B, Kim Y, Tsang J. Plasma levels of endothelin-1, big endothelin-1 and thromboxane following acute pulmonary air embolism. *Respir Physiol Neurobiol* 2003;138:97–106.
147. Schmeck J, Koch T, Patt B, Heller A, Neuhof H, van Ackern K. The role of endothelin-1 as a mediator of the pressure response after air embolism in blood perfused lungs. *Intensive Care Med* 1998;24:605–611.
148. Tsang J, Battistini B, Dussault P, Stewart K, Qayumi K. Biphasic release of immunoreactive endothelins following acute pulmonary thromboembolism. *J Cardiovasc Pharmacol* 2000;36:S221–S224.
149. Dschietzig T, Laule M, Alexiou K, Schror K, Baumann G, Stangl K. Coronary constriction and consequent cardiodepression in pulmonary embolism are mediated by pulmonary big endothelin and enhanced in early endothelial dysfunction. *Crit Care Med* 1998;26:510–517.
150. Szabo RRG, Minnear FL, Bizios R, Johnson A, Malik AB. Role of thromboxane in the pulmonary response to pulmonary microembolism. *Chest* 1983;83(suppl.):76S–78S.
151. Egermayer P, Town GI, Peacock AJ. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. *Thorax* 1999;54:161–168.
152. Searle NR, Sahab P. Endothelial vasomotor regulation in health and disease. *Can J Anesth* 1992;39:838–857.
153. Battistini B. Modulation and roles of the endothelins in the pathophysiology of pulmonary embolism. *Can J Physiol Pharmacol* 2003;81:555–569.
154. Schini VB, Hendrickson H, Heublein DM, Burnett JC Jr, Vanhoutte PM. Thrombin enhances the release of endo-

- thelin from cultured porcine aortic endothelial cells. *Eur J Pharmacol* 1989;165:333–334.
155. Tsang JY, Lamm WJE. Estimation of endothelin-mediated vasoconstriction in acute pulmonary thromboembolism. *Pulm Circ* 2012;2:67–74.
 156. Hasinoff I, Ducas J, Schick U, Prewitt RM. Pulmonary vascular pressure flow characteristics in canine pulmonary embolism. *J Appl Physiol* 1990;68:462–467.
 157. Bshouty Z, Younes M. Distensibility and pressure flow relationship of pulmonary circulation. I. Single-vessel model. *J Appl Physiol* 1990;68:1501–1513.
 158. Bshouty Z, Younes M. Distensibility and pressure flow relationship of pulmonary circulation. II. Multibranched model. *J Appl Physiol* 1990;68:1514–1527.
 159. Delcroix M, Mélot C, Vachiéry JL, Lejeune P, Leeman M, Vanderhoeft P, Naeije R. Effects of embolus size on hemodynamics and gas exchange in canine embolic pulmonary hypertension. *J Appl Physiol* 1990;69:2254–2261.
 160. Clark AR, Burrows KS, Tawhai MH. The impact of micro-embolism size on haemodynamic changes in the pulmonary micro-circulation. *Respir Physiol Neurobiol* 2011;175:365–374.
 161. Fung YC, Sobin SS. Pulmonary alveolar blood flow. *Circ Res* 1972;30:470–490.
 162. Dalen JE, Alpert JS. Natural history of pulmonary embolism. *Prog Cardiovasc Dis* 1975;17:259–269.
 163. Tsang J, Lamm W, Neradilek B, Polissar N, Hlastala M. Endothelin receptor blockade does not improve hypoxemia following acute pulmonary thromboembolism. *J Appl Physiol* 2007;102:762–771.
 164. Mélot C, Naeije R, Mols P, Hallemans R, Lejeune P, Jaspar N. Pulmonary vascular tone improves pulmonary gas exchange in the adult respiratory distress syndrome. *Am Rev Respir Dis* 1987;136:1232–1236.
 165. Dantzker DR, Bower JS. Pulmonary vascular tone improves $\dot{V}_A/\dot{Q}$ matching in obliterative pulmonary hypertension. *J Appl Physiol* 1981;51:607–613.
 166. Delcroix M, Mélot C, Lejeune P, Leeman M, Naeije R. Effects of vasodilators on gas exchange in acute canine embolic pulmonary hypertension. *Anesthesiology* 1990;72:77–84.
 167. Pagnamenta A, Fesler P, Vandinivit A, Brimioulle S, Naeije R. Pulmonary vascular effects of dobutamine in experimental hypertension. *Crit Care Med* 2003;31:1140–1146.
 168. Kooter AJ, Uzerman RG, Kamp O, Boonstra AB, Smulders YM. No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial. *BMC Pulm Med* 2010;10:18.
 169. Sasahara A. Pulmonary vascular response to thromboembolism. *Mod Concepts Cardiovasc Dis* 1967;36:55–70.
 170. McIntyre KM, Sasahara AA. Angiography, scanning and hemodynamics in pulmonary embolism: critical review and correlations. *CRC Crit Rev Radiol Sci* 1972;3:489–521.
 171. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE, National Emphysema Treatment Trial Research Group. Hemodynamic characterization of patients with severe emphysema. *Am J Respir Crit Care Med* 2002;166:314–322.